System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Yannick Bidet is an expert in Oncology at Centre Jean Perrin (France). Yannick Bidet has authored 66 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 2 of them ongoing. SLR score: 185 (community average: 125). How the SLR is computed.

LeadR Profile

Yannick Bidet Centre Jean Perrin France
185 ScienceLeadR Reputation 185

Unlock

Register Login
Network Map

Oncology

Subspecialties: Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 66

Citations

Citations: 1 056 1st author: 1 Last author: 6 Unique author: 1

Main journals

Cancer Res 7
Clin Genet 3
Front Oncol 3
HAL (Le Centre pour la Communication Scientifique Directe) 3
Am J Cancer Res 2

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Molecular mechanisms underlying opportunistic seasonal reproduction in the male rodent pest Arvicola terrestris scherman.
PMID 42062439 — reproduction, tissues		Sci Rep20260
Case Report: Expansion of the POLD1-related polymerase proofreading-associated polyposis spectrum: first report of duodenal adenocarcinomas and characterization of two likely pathogenic variants.
PMID 41487566 — neoplasms, adenocarcinoma, immunotherapy		Front Oncol20250
Identification of serum proteins associated with response of triple-negative breast cancer to neoadjuvant chemotherapy: preliminary results from the INSTIGO trial.
PMID 41462069 — triple negative breast neoplasms, serum, breast neoplasms, neoplasms, drug therapy, biomarkers, breast, chemotherapy		Clin Proteomics20250
Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma.
PMID 41143943 — cells, proteoglycans, pharmaceutical preparations, neoplasms, chondrosarcoma, multimodal imaging, therapeutics		EJNMMI Res20250
Development and validation of a next-generation sequencing-based method for calculating the breast cancer polygenic risk score PRS 313.
PMID 40974665 — genes, high-throughput nucleotide sequencing, breast neoplasms, workflow, neoplasms, breast, genetic risk score		Breast20250

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 4

By status:

Active not recruiting 2
Recruiting 2

By type:

Interventional 2
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma
NCT06550674 — genes, blood, melanoma, neoplasms, diagnosis, thyroid neoplasms, research, exome, history, wounds and injuries, uveal melanoma		N/ARecruiting2024
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
NCT04133077 — serology, blood, breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics, heterografts, prospective studies, female		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS